10.11
0.80%
0.08
전일 마감가:
$10.03
열려 있는:
$10.05
하루 거래량:
739.79K
Relative Volume:
0.40
시가총액:
$539.13M
수익:
$1.02B
순이익/손실:
$-757.20M
주가수익비율:
-0.8369
EPS:
-12.08
순현금흐름:
$-257.90M
1주 성능:
+13.85%
1개월 성능:
+13.21%
6개월 성능:
+112.39%
1년 성능:
+388.41%
Emergent Biosolutions Inc Stock (EBS) Company Profile
명칭
Emergent Biosolutions Inc
전화
240-631-3200
주소
300 PROFESSIONAL DR, GAITHERSBURG, MD
EBS을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
10.11 | 539.13M | 1.02B | -757.20M | -257.90M | -12.08 |
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-08-22 | 개시 | Rodman & Renshaw | Buy |
2024-03-07 | 업그레이드 | The Benchmark Company | Hold → Buy |
2023-11-20 | 재개 | JP Morgan | Underweight |
2023-08-29 | 다운그레이드 | The Benchmark Company | Buy → Hold |
2023-04-10 | 업그레이드 | The Benchmark Company | Hold → Buy |
2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2022-11-10 | 다운그레이드 | The Benchmark Company | Buy → Hold |
2022-04-29 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
2022-01-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
2021-11-08 | 다운그레이드 | The Benchmark Company | Buy → Hold |
2021-05-05 | 다운그레이드 | Argus | Buy → Hold |
2021-04-07 | 개시 | The Benchmark Company | Buy |
2021-02-24 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
2021-02-19 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2020-09-14 | 재개 | JP Morgan | Neutral |
2020-07-31 | 재확인 | Chardan Capital Markets | Buy |
2019-09-12 | 개시 | Guggenheim | Buy |
2019-09-04 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
2018-11-02 | 업그레이드 | Goldman | Neutral → Buy |
2018-08-03 | 재확인 | Chardan Capital Markets | Buy |
2018-06-13 | 개시 | Argus | Buy |
2018-04-25 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
2018-01-24 | 개시 | Goldman | Neutral |
2018-01-16 | 재확인 | Chardan Capital Markets | Buy |
2016-06-28 | 재확인 | Singular Research | Buy |
2016-04-15 | 개시 | Chardan Capital Markets | Buy |
2016-03-28 | 개시 | Singular Research | Buy |
2016-02-19 | 개시 | Wells Fargo | Outperform |
2014-05-15 | 개시 | Summer Street Research | Buy |
2011-05-31 | 재확인 | WBB Securities | Strong Buy |
2011-01-10 | 재확인 | Wedbush | Outperform |
2010-11-05 | 재확인 | Wedbush | Outperform |
2010-08-18 | 업그레이드 | WBB Securities | Buy → Strong Buy |
2010-08-06 | 재확인 | Caris & Company | Buy |
모두보기
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks - MSN
Emergent's Vaccine Production Failure: Contamination Scandal, Investor Backlash, and $40M Settlement - Benzinga
Emergent BioSolutions Inc. (NYSE:EBS) Q3 2024 Earnings Call Transcript - MSN
Emergent BioSolutions (NYSE:EBS) Stock Rating Lowered by StockNews.com - MarketBeat
Insider Sale: Director Donald Degolyer Sells 25,000 Shares of Em - GuruFocus.com
Emergent BioSolutions director Donald DeGolyer sells $272,750 in stock - Investing.com
Emergent BioSolutions director Donald DeGolyer sells $272,750 in stock By Investing.com - Investing.com UK
Oak Hill Advisors LP's Strategic Acquisition of Emergent BioSolu - GuruFocus.com
Insider Sale: Director Marvin White Sells 14,287 Shares of Emergent BioSolutions Inc (EBS) - GuruFocus.com
Smallpox Treatment Market Is Anticipated To Grow In A Promising - openPR
Emergent BioSolutions Inc (EBS) Shares Down 8.02% on Nov 12 - GuruFocus.com
IDWeek 2024: strategic approaches and challenges in mpox vaccination - Pharmaceutical Technology
Emergent BioSolutions Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Emergent BioSolutions (NYSE:EBS) Shares Up 7.9% After Analyst Upgrade - MarketBeat
Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights - GuruFocus.com
Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic (NYSE:EBS) - Seeking Alpha
Emergent Biosolutions Stock Soars After Q3 Earnings: Retail Sentiment Strong - MSN
Overdose Crisis In Shadows Of Elections As Black, Indigenous Americans Deaths Rise - Benzinga
Emergent BioSolutions Inc (EBS) Quarterly 10-Q Report - Quartzy
Emergent BioSolutions entering ‘turnaround’ phase, new CEO says - The Business Journals
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 - Yahoo Finance
Crude Oil Rises 1%; US Jobless Claims Increase To 221,000 - Benzinga
Emergent BioSolutions (NYSE:EBS) Shares Gap Up on Analyst Upgrade - MarketBeat
Emergent Biosolutions Shares Surge 28% After Swinging to 3Q Profit - MarketWatch
Emergent BioSolutions stock target increased, keeps buy on strong Q3 By Investing.com - Investing.com UK
The Post-Trump Victory TradeEmergent BioSolutions (NYSE:EBS), Bit Digital (NASDAQ:BTBT) - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Emergent Biosolutions: Q3 Earnings Snapshot - Houston Chronicle
Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript - AOL
Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates - Yahoo Finance
Emergent Biosolutions stock jumps 14% post-market on guidance raise (NYSE:EBS) - Seeking Alpha
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa - The Manila Times
The Escalator: Emergent BioSolutions, CureVac, Kyowa Kirin and more - MM+M Online
Emergent BioSolutions Reports Third Quarter 2024 Financial Results - The Manila Times
Emergent BioSolutions Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Emergent Bio slips after financing deal - MSN
Emergent BioSolutions appoints new chief medical officer By Investing.com - Investing.com Canada
Biotech Co. Emergent Gives Interim GC Permanent Role - Law360
Emergent BioSolutions appoints new chief medical officer - Investing.com
Emergent BioSolutions (EBS) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Emergent Bio's smallpox vaccine gets US approval for mpox - AOL
Assenagon Asset Management S.A. Increases Stock Position in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way? - Simply Wall St
Zacks.com featured highlights include American Airlines, Air Canada, EmergentBioSolutions, Berry and Cracker Barrel Old Country Store - Yahoo Finance
5 Broker Liked Stocks to Keep an Eye on After Recent Analyst Upgrades - Yahoo Finance
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - GlobeNewswire Inc.
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024 - The Manila Times
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference - The Bakersfield Californian
Emergent BioSolutions (NYSE:EBS) Shares Up 3.2%Here's What Happened - MarketBeat
Biopharma Layoffs Roundup - Contract Pharma
Emergent Biosolutions Inc (EBS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):